Infections caused by Candida spp. in patients with COVID-19: A literature review

Authors

  • M. Silva Fiorio Departament of Analysis, Faculty of Pharmacy, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
  • C. G. dos Santos do Nascimento Departament of Analysis, Faculty of Pharmacy, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
  • P. Abreu Pereira Departament of Analysis, Faculty of Pharmacy, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
  • B. Cervinski Junges Departament of Analysis, Faculty of Pharmacy, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
  • S. Krolow Departament of Analysis, Faculty of Pharmacy, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
  • V. Marcon Giudice Departament of Analysis, Faculty of Pharmacy, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.
  • F. Costa Charles Departament of Analysis, Faculty of Pharmacy, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
  • L. Cervieri Mezzomo Departament of Analysis, Faculty of Pharmacy, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
  • S. M. Spalding Departament of Analysis, Faculty of Pharmacy, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
  • L. Noal Calil Departament of Analysis, Faculty of Pharmacy, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
  • A. Mezzari Departament of Analysis, Faculty of Pharmacy, Federal University of Rio Grande do Sul, Porto Alegre, Brazil

Abstract

Objectives: This review aimed to evaluate the frequency of infections caused by yeasts of Candida spp. in patients affected with COVID-19. Materials and methods: A literature review was carried out in the Pubmed, Medline and Scielo databases, using the following keywords: Candida spp.” AND “COVID 19” AND “Candidiasis” AND “Candida”. The selected studies present data about the types of infection, fungal isolates and the treatment employed. Results: There is an increase in mortality rates in individuals co-infected with COVID-19 and Candida spp., especially in those with associated risk factors. The most frequent species were Candida albicans, C. glabrata, C. tropicalis and C. auris. Furthermore, candidemia and oropharyngeal candidiasis were the clinical forms mentioned in association with COVID-19. Management is also dependent on the clinical form and the classes of antifungal agents recommended and/or tested in these studies are azoles, echinocandins and polyenes. Conclusion: Co-infection by Candida spp. and COVID-19 leads to a worrying scenario in which the number of cases has increased around the world, causing higher mortality rates in these patients. This increase was evident throughout the study, as well as emphasizyng the importance of correct identification and management of these infections

Keywords:

Candida spp., Candidiasis, COVID-19, Sars-CoV-2

Downloads

Download data is not yet available.

Published

01-01-2022
Statistics
49 Views | 54 Downloads

How to Cite

M. Silva Fiorio, C. G. dos Santos do Nascimento, P. Abreu Pereira, B. Cervinski Junges, S. Krolow, V. Marcon Giudice, F. Costa Charles, L. Cervieri Mezzomo, S. M. Spalding, L. Noal Calil, and A. Mezzari. “Infections Caused by Candida Spp. In Patients With COVID-19: A Literature Review”. Journal of Innovations in Pharmaceutical and Biological Sciences, vol. 9, no. 1, Jan. 2022, pp. 07-16, https://jipbs.com/index.php/journal/article/view/416.

Issue

Section

Review Article